SynthesisClinical and molecular hepatology2022
Global prevalence of depression and anxiety in patients with hepatocellular carcinoma: Systematic review and meta-analysis.
Synthesis in Clinical and molecular hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Global prevalence and determinant factors of pain, depression, and anxiety among cancer patients: an umbrella review of systematic reviews and meta-analyses.BMC psychiatry · 2025Pooled it
- Global research trends on gastrointestinal cancer and mental health (2004-2024): a bibliographic study.Frontiers in medicine · 2025Pooled it
- Article
- [Construction of an anxiety recognition model for patients with malignant gastrointestinal tumors based on multidimensional features and multiple interpretable machine learning].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Chronic stress disrupts hepatic homeostasis and accelerates liver cancer progression through ADRB2 signaling.Science advances · 2026Article
- Quality of life in patients with hepatocellular carcinoma: a bibliometric analysis.Discover oncology · 2026Article
- Treatment-related differences in quality of life and psychological distress among patients with hepatocellular carcinoma: A cross-sectional analysis.Palliative & supportive care · 2026Article
- Joint latent profiles of death anxiety and treatment adherence in HCC patients.Frontiers in psychiatry · 2026Article
- Management of Advanced Hepatocellular Carcinoma: A Review and Practical Guide.JCO oncology practice · 2025Review
- Sini Powder Alleviates Stress Response and Suppresses Hepatocellular Carcinoma Development by Restoring Gut Microbiota.Chinese journal of integrative medicine · 2025Article
- Article
- Educational, financial, logistical, emotional, and social needs among patients with hepatocellular carcinoma.Hepatology communications · 2025Article
- Factors influencing anxiety and depression in advanced hepatocellular carcinoma patients and their impact on quality of life.World journal of psychiatry · 2025Article
- Molecular mechanisms and clinical value of the correlation between depression and cancer.Medical oncology (Northwood, London, England) · 2025Review
- Greater Symptom Burden and Poorer Quality of Life Outcomes Are Associated With The Co-Occurrence of Anxiety and Depression During Cancer Chemotherapy.Seminars in oncology nursing · 2025Article
- Depressive symptoms and immune depletion in Chinese patients with advanced hepatocellular carcinoma: a multicentre study on their correlation.General psychiatry · 2025Article
- Ansofaxine Hydrochloride inhibits hepatocellular carcinoma growth and enhances targeted therapy through the EGFR/MAPK pathway.Frontiers in oncology · 2025Article
- Association between olanzapine and immune function in lung cancer patients with anxiety and depression: a retrospective cohort study of medical records.Frontiers in psychiatry · 2025Article
- Associations of tumor-related psychiatric symptoms and healthy behaviors with dynamic quality of life after hepatocellular carcinoma hepatectomy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Psychiatric disorders in patients with hepatocellular carcinoma: A large US cohort of commercially insured individuals.Alimentary pharmacology & therapeutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsDepression and anxiety are associated with poorer outcomes in patients with hepatocellular carcinoma (HCC). However, the prevalence of depression and anxiety in HCC are unclear. We aimed to establish the prevalence of depression and anxiety in patients with HCC.
methodsMEDLINE and Embase were searched and original articles reporting prevalence of anxiety or depression in patients with HCC were included. A generalized linear mixed model with Clopper-Pearson intervals was used to obtain the pooled prevalence of depression and anxiety in patients with HCC. Risk factors were analyzed via a fractional-logistic regression model.
resultsSeventeen articles involving 64,247 patients with HCC were included. The pooled prevalence of depression and anxiety in patients with HCC was 24.04% (95% confidence interval [CI], 13.99-38.11%) and 22.20% (95% CI, 10.07-42.09%) respectively. Subgroup analysis determined that the prevalence of depression was lowest in studies where depression was diagnosed via clinician-administered scales (16.07%;95% CI, 4.42-44.20%) and highest in self-reported scales (30.03%; 95% CI, 17.19-47.01%). Depression in patients with HCC was lowest in the Americas (16.44%; 95% CI, 6.37-36.27%) and highest in South-East Asia (66.67%; 95% CI, 56.68-75.35%). Alcohol consumption, cirrhosis, and college education significantly increased risk of depression in patients with HCC.
conclusionOne in four patients with HCC have depression, while one in five have anxiety. Further studies are required to validate these findings, as seen from the wide CIs in certain subgroup analyses. Screening strategies for depression and anxiety should also be developed for patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.